Formulation of Biocompatible Targeted ECO/siRNA Nanoparticles with Long-Term Stability for Clinical Translation of RNAi

Overview

Journal Nucleic Acid Ther

Specialties Biochemistry
Molecular Biology
Pharmacology

Date 2019 May 30

PMID 31140918

Citations 16

Authors

Nadia R Ayat

Zhanhu Sun

Da Sun

Michelle Yin

Ryan C Hall

Amita M Vaidya

Xujie Liu

Andrew L Schilb

Josef H Scheidt

Zheng-Rong Lu

Affiliations

Soon will be listed here.

Abstract

Nanoparticle based siRNA formulations often suffer from aggregation and loss of function during storage. We in this study report a frozen targeted RGD-polyethylene glycol (PEG)-ECO/siβ3 nanoparticle formulation with a prolonged shelf life and preserved nanoparticle functionality. The targeted RGD-PEG-ECO/siβ3 nanoparticles are formed by step-wised self-assembly of RGD-PEG-maleimide, ECO, and siRNA. The nanoparticles have a diameter of 224.5 ± 9.41 nm and a zeta potential to 45.96 ± 3.67 mV in water and a size of 234.34 ± 3.01 nm and a near neutral zeta potential in saline solution. The addition of sucrose does not affect their size and zeta potential and substantially preserves the integrity and biological activities of frozen and lyophilized formulations of the targeted nanoparticles. The frozen formulation with as low as 5% sucrose retains nanoparticle integrity (90% siRNA encapsulation), size distribution (polydispersity index [PDI] ≤20%), and functionality (at least 75% silencing efficiency) at -80°C for at least 1 year. The frozen RGD-PEG-ECO/siβ3 nanoparticle formulation exhibits excellent biocompatibility, with no adverse effects on hemocompatibility and minimal immunogenicity. As RNAi holds the promise in treating the previously untreatable diseases, the frozen nanoparticle formulation with the low sucrose concentration has the potential to be a delivery platform for clinical translation of RNAi therapeutics.

Citing Articles

MR Molecular Image Guided Treatment of Pancreatic Cancer with Targeted ECO/miR-200c Nanoparticles in Immunocompetent Mouse Tumor Models.

Laney V, Hall R, Yuan X, Hampson E, Halle A, Yeung G Pharm Res. 2024; 41(9):1811-1825.

PMID: 39198318 PMC: 11436418. DOI: 10.1007/s11095-024-03762-7.

Intravitreal Delivery of PEGylated-ECO Plasmid DNA Nanoparticles for Gene Therapy of Stargardt Disease.

Sun D, Sun W, Gao S, Lehrer J, Wang H, Hall R Pharm Res. 2024; 41(4):807-817.

PMID: 38443629 DOI: 10.1007/s11095-024-03679-1.

Evaluating Dual-Targeted ECO/siRNA Nanoparticles against an Oncogenic lncRNA for Triple Negative Breast Cancer Therapy with Magnetic Resonance Molecular Imaging.

Nicolescu C, Schilb A, Kim J, Sun D, Hall R, Gao S Chem Biomed Imaging. 2023; 1(5):461-470.

PMID: 37655165 PMC: 10466452. DOI: 10.1021/cbmi.3c00011.

Enhancing chemical and physical stability of pharmaceuticals using freeze-thaw method: challenges and opportunities for process optimization through quality by design approach.

Bernal-Chavez S, Romero-Montero A, Hernandez-Parra H, Pena-Corona S, Del Prado-Audelo M, Alcala-Alcala S J Biol Eng. 2023; 17(1):35.

PMID: 37221599 PMC: 10207779. DOI: 10.1186/s13036-023-00353-9.

Research Advances on the Stability of mRNA Vaccines.

Cheng F, Wang Y, Bai Y, Liang Z, Mao Q, Liu D Viruses. 2023; 15(3).

PMID: 36992377 PMC: 10051489. DOI: 10.3390/v15030668.

References

Chacon M, Molpeceres J, Berges L, Guzman M, Aberturas M . Stability and freeze-drying of cyclosporine loaded poly(D,L lactide-glycolide) carriers. Eur J Pharm Sci. 1999; 8(2):99-107. DOI: 10.1016/s0928-0987(98)00066-9. View

Leung R, Whittaker P . RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther. 2005; 107(2):222-39. PMC: 7112686. DOI: 10.1016/j.pharmthera.2005.03.004. View

Helal Neto E, Coelho A, Sampaio A, Henriques M, Marcinkiewicz C, de Freitas M . Activation of human T lymphocytes via integrin signaling induced by RGD-disintegrins. Biochim Biophys Acta. 2006; 1773(2):176-84. DOI: 10.1016/j.bbamcr.2006.09.026. View

Abdelwahed W, Degobert G, Stainmesse S, Fessi H . Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev. 2006; 58(15):1688-713. DOI: 10.1016/j.addr.2006.09.017. View

Andersen M, Howard K, Paludan S, Besenbacher F, Kjems J . Delivery of siRNA from lyophilized polymeric surfaces. Biomaterials. 2007; 29(4):506-12. DOI: 10.1016/j.biomaterials.2007.10.003. View

Aleku M, Schulz P, Keil O, Santel A, Schaeper U, Dieckhoff B . Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res. 2008; 68(23):9788-98. DOI: 10.1158/0008-5472.CAN-08-2428. View

Chen C, Hou W, Liu I, Hsiao G, Huang S, Huang J . Inhibitors of clathrin-dependent endocytosis enhance TGFbeta signaling and responses. J Cell Sci. 2009; 122(Pt 11):1863-71. PMC: 2684837. DOI: 10.1242/jcs.038729. View

Nieswandt B, Varga-Szabo D, Elvers M . Integrins in platelet activation. J Thromb Haemost. 2009; 7 Suppl 1:206-9. DOI: 10.1111/j.1538-7836.2009.03370.x. View

Dobrovolskaia M, Patri A, Potter T, Rodriguez J, Hall J, McNeil S . Dendrimer-induced leukocyte procoagulant activity depends on particle size and surface charge. Nanomedicine (Lond). 2011; 7(2):245-56. DOI: 10.2217/nnm.11.105. View

10.

Dobrovolskaia M, Patri A, Simak J, Hall J, Semberova J, Lacerda S . Nanoparticle size and surface charge determine effects of PAMAM dendrimers on human platelets in vitro. Mol Pharm. 2011; 9(3):382-93. PMC: 3624701. DOI: 10.1021/mp200463e. View

11.

Kundu A, Chandra P, Hazari S, Ledet G, Pramar Y, Dash S . Stability of lyophilized siRNA nanosome formulations. Int J Pharm. 2011; 423(2):525-34. PMC: 3298087. DOI: 10.1016/j.ijpharm.2011.11.040. View

12.

Kim T, Afonin K, Viard M, Koyfman A, Sparks S, Heldman E . In Silico, In Vitro, and In Vivo Studies Indicate the Potential Use of Bolaamphiphiles for Therapeutic siRNAs Delivery. Mol Ther Nucleic Acids. 2013; 2:e80. PMC: 3615820. DOI: 10.1038/mtna.2013.5. View

13.

Ilinskaya A, Dobrovolskaia M . Nanoparticles and the blood coagulation system. Part II: safety concerns. Nanomedicine (Lond). 2013; 8(6):969-81. PMC: 3939602. DOI: 10.2217/nnm.13.49. View

14.

Dobrovolskaia M, McNeil S . Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. J Control Release. 2013; 172(2):456-66. PMC: 5831149. DOI: 10.1016/j.jconrel.2013.05.025. View

15.

Kasper J, Troiber C, Kuchler S, Wagner E, Friess W . Formulation development of lyophilized, long-term stable siRNA/oligoaminoamide polyplexes. Eur J Pharm Biopharm. 2013; 85(2):294-305. DOI: 10.1016/j.ejpb.2013.05.010. View

16.

Malamas A, Gujrati M, M Kummitha C, Xu R, Lu Z . Design and evaluation of new pH-sensitive amphiphilic cationic lipids for siRNA delivery. J Control Release. 2013; 171(3):296-307. PMC: 4060977. DOI: 10.1016/j.jconrel.2013.06.019. View

17.

Garba A, Mousa S . Bevasiranib for the treatment of wet, age-related macular degeneration. Ophthalmol Eye Dis. 2013; 2:75-83. PMC: 3661434. DOI: 10.4137/OED.S4878. View

18.

Gujrati M, Malamas A, Shin T, Jin E, Sun Y, Lu Z . Multifunctional cationic lipid-based nanoparticles facilitate endosomal escape and reduction-triggered cytosolic siRNA release. Mol Pharm. 2014; 11(8):2734-44. PMC: 4457381. DOI: 10.1021/mp400787s. View

19.

Schultheis B, Strumberg D, Santel A, Vank C, Gebhardt F, Keil O . First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. J Clin Oncol. 2014; 32(36):4141-8. DOI: 10.1200/JCO.2013.55.0376. View

20.

Lorenzer C, Dirin M, Winkler A, Baumann V, Winkler J . Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics. J Control Release. 2015; 203:1-15. DOI: 10.1016/j.jconrel.2015.02.003. View